Evidence map›Paper›PMID 41415380›Full record

ArticlebioRxiv : the preprint server for biology2025

Human stem cell models for group 3 medulloblastoma uncover JARID1B as a regulator of the chromatin landscape.

Zulekha A Qadeer, Elise Hou, Dara Siegel, Samantha Westelman, Brian Gudenas, Kyle Smith, Wazim Mohammed Ismael, Linyu Wang, Mackenzie O Johnson, Shane Grele and 8 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Zulekha A QadeerDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-1335-660X
Elise HouDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.
Dara SiegelDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.
Samantha WestelmanDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.
Brian GudenasCenter of Excellence in Neuro-Oncology Sciences, St. Jude Children's Research Hospital, Memphis, TN USA.
Kyle SmithCenter of Excellence in Neuro-Oncology Sciences, St. Jude Children's Research Hospital, Memphis, TN USA.
Wazim Mohammed IsmaelDivision of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN USA.
Linyu WangDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.
Mackenzie O JohnsonDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.
Shane GreleDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.
Ronald PhuaDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.
Liam HendrikseDevelopmental and Stem Cell Biology, Hospital for Sick Children, Toronto, ON, Canada.
Ekin GuneyDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.
Miller HuangDepartment of Pediatrics, University of Southern California, Los Angeles, CA, USA.
Alexandre Gaspar-MaiaDivision of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN USA.
Paul A NorthcottCenter of Excellence in Neuro-Oncology Sciences, St. Jude Children's Research Hospital, Memphis, TN USA.
Michael D TaylorDevelopmental and Stem Cell Biology, Hospital for Sick Children, Toronto, ON, Canada.
William A WeissDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alan Ashworth · 1999 to 2026
$209.7M
Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4M
Training Program in Translational Brain Tumor ResearchT32CA151022 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2010 to 2026
$6.6M
Illumina NovaSeq 6000 Sequencing SystemS10OD028511 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHOW, ERIC D · 2020 to 2020
$583k
NCI NIH HHS P30 CA082103NCI NIH HHS P50 CA097257NCI NIH HHS T32 CA151022NIH HHS S10 OD028511
6 · The paper itself

Abstract

Medulloblastoma (MB) is one of the most prevalent malignant brain tumors in children, with tremendous cognitive and neuroendocrine disability among survivors. Group 3 MB (G3MB) has poor overall survival at <50%, high frequencies of metastases, and no targeted therapies. Amplification of

Identifiers

PMID41415380
PMCPMC12709477

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.